Contact the Editorial Desk

Editorial correspondence

Integrative Peptide welcomes correspondence on the research record itself: a citation quoted inaccurately, a trial that has published new results, a regulatory-status change, or a peer-reviewed study on AOD-9604, retatrutide, semaglutide, or tesamorelin that should be added to the references page. Corrections that improve the accuracy or currency of the index are the most useful class of message this desk receives, and each is read carefully.

The most actionable submissions specify the page in question, the exact passage being challenged, and a supporting reference, a DOI or PubMed identifier wherever possible, so a proposed change can be checked against its source before anything is updated.

Editorial mailbox: editors@integrativepeptide.com

What this desk cannot do

Integrative Peptide is a literature index, not a clinical service or a product vendor, so it cannot advise on or recommend human use of any peptide discussed here; suggest a dose, schedule, or route of administration for any individual; judge whether a cited trial finding applies to a specific person's situation; or sell, source, or help locate any compound from any supplier. It also cannot advise athletes on anti-doping questions, given that AOD-9604 and tesamorelin fall under active WADA monitoring categories.

Semaglutide and tesamorelin are prescription medicines. Retatrutide is investigational and not legally available outside registered trials. AOD-9604 has no approved human use. Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed.